Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sana Biotechnology Inc (SANA) vs Yum! Brands, Inc. (YUM) Price & Performance

Sana Biotechnology IncTrade
Yum! Brands, Inc.Trade

Price performance (Past 24H)

Key statistics

Sana Biotechnology Inc vs Yum! Brands, Inc. — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Yum! Brands, Inc. trades at $150.01 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 35× Sana Biotechnology Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

SANAYUM
Market Cap
$1.13B$39.50B
Sector
HealthConsumer Cyclical
52-Week High
$5.92$168.16
52-Week Low
$2.68$138.21
Enterprise Value
$1.05B$51.10B
Dividend Yield
2.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.

Yum! Brands, Inc.

YUM trades at $150.15, up 3.32% in the past 24 hours, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show a Q2 2026 beat with EPS of $1.62 versus $1.57 expected, while revenue grew to $8.21B in 2025. The company completed the sale of Pizza Hut China for $1.2B in August 2026, aiming to streamline operations and reduce debt. Cash flow from operations improved to $2.01B in 2025, supporting a dividend payment of $0.75 per share.

The outlook is mixed, with analyst consensus leaning hold (56.87%) but a price target of $174.60 implying 16% upside. Risks include ongoing legal investigations and a parasite outbreak impacting Taco Bell sales, though management reports recovery. Debt remains high at $11.25B long-term, but the debt-to-asset ratio improved to 143.49 in 2025. Execution on digital growth and brand focus post-Pizza Hut sale are key to unlocking value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA

About Yum! Brands, Inc.

Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.

Read more on YUM